Loading company…
Based in Hangzhou and established in 2015, Pulmed is a clinical-stage biotech developing inhalation therapies for respiratory diseases.
Based in Hangzhou, China and established in 2015, Pulmed is a clinical-stage biotechnology company focused on discovering, developing and commercializing inhalation therapies for respiratory diseases. In 2020 it completed a pivotal BE study for CXF11, and in 2021 it signed a license-in deal with Aerami Therapeutics for PAH treatment. Its inhalation products use two proprietary platforms covering powder formulation and inhaler design.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in